期刊文献+

基于T>MIC简易数学模型对二室模型的拓展适用性探讨美罗培南给药方案 被引量:6

Meropenem regimens based on the simple mathematical model of T>MIC for two-compartment model
下载PDF
导出
摘要 目的考察T>MIC简易数学模型对二室模型的适用性,简化T>MIC计算过程,并据此探讨美罗培南给药方案。方法以美罗培南的推荐剂量和静脉输注时间分别为0.5h与3h设计6种临床常用方案(0.5g/次q8h0.5h、0.5g/次q8h3h、1.0g/次q8h0.5h、1.0g/次q8h3h、2.0g/次q8h0.5h、2.0g/次q8h3h),各方案分别与美罗培南对临床常见致病菌的4种MIC敏感性折点(0.5、1、2、4μg/ml)组合形成不同的T>MIC,每种方案的T>MIC又可根据简易模型和二室模型计算,结果形成不同方案下的T>MIC对子,T>MIC差异采用配对样本t检验,考察简易数学模型的拓展适用性。并根据简易模型计算T>MIC%,以其达到40%~100%探讨美罗培南对不同细菌感染的给药方案。结果与结论简易模型可替代二室模型计算T>MIC,根据该模型从理论上可方便快捷地对美罗培南给药方案进行初判和模拟优化。 Objective To simplify the calculation of T MIC and evaluate meropenem regimens based on the simple mathematical model of T〉MIC reported in literature for two-compartment model .Methods Six meropenem regimens were de-signed according to the recommended dose with the infusion duration of 0 .5 h and 3 h . Four different MIC susceptibility break-point of meropenem against clinical microbiologic flora were used to formulate different TMIC .Each TMIC was calculated by both the simple and two-compartment model of T〉MIC .Meropenem regimens were evaluated for different bacterial infec-tions based on the simple model of T〉MIC with 40% ?100% of the T〉MIC% as the target. The t-test suggested no signifi-cant difference between the pairs of TMIC calculated by the two models .Results and Conclusion Simple model of T〉MIC can replace the two-compartment model .Meropenem regimens can be optimized based on this simple model of TMIC conven-iently and quickly .
作者 陈瑶 宋香清
出处 《药学实践杂志》 CAS 2017年第4期341-345,共5页 Journal of Pharmaceutical Practice
关键词 T〉MIC 碳青霉烯 美罗培南 一室模型 二室模型 times above MIC (TMIC ) carbapenem meropenem one-compartment model two-compartment model
  • 相关文献

参考文献4

二级参考文献32

  • 1周颖杰,李光辉.成人及儿童复杂性腹腔内感染的诊断与处理:美国外科感染学会及美国感染病学会指南[J].中国感染与化疗杂志,2010,10(4):241-247. 被引量:233
  • 2姚国新,汤远亮,张丽华.头孢曲松T>MIC达标的影响因素分析[J].现代医药卫生,2007,23(10):1452-1453. 被引量:2
  • 3汤远亮,姚国新,张丽华.不同剂量和给药速度对头孢唑啉T>MIC达标的影响[J].海峡药学,2007,19(6):23-24. 被引量:2
  • 4卫生部,国家中医药管理局,总后卫生部.抗菌药物临床应用指导原则[S].卫医发[2004]285号.
  • 5Lee LS,Kinzig-Schippers M,Nafziger AN,et al.Comparisonof 30-min and 3-h infusion regimens for imipenem/cilastatin and formeropenem evaluated by Monte Carlo simulation[J].Diagn Micro-biol Infect Dis,2010,68(3):251-258.
  • 6Li C,Kuti JL,Nightingale CH,et al.Population pharmacoki-netic analysis and dosing regimen optimization of meropenem inadult patients[J].J Clin Pharmacol,2006,46(10):1171-1178.
  • 7Zhou QT,He B,Zhang C,et al.Pharmacokinetics and pharma-codynamics of meropenem in elderly chinese with lower respira-tory tract infections:population pharmacokinetics analysis usingnonlinear mixed-effects modelling and clinical pharmacodynamicsstudy[J].Drugs Aging,2011,28(11):903-912.
  • 8Lee DG,Choi SM,Shin WS,et al.Population pharmacokineticsof meropenem in febrile neutropenic patients in Korea[J].Int J Anti-microb Agents,2006,28(4):333-339.
  • 9Doh K,Woo H,Hur J,et al.Population pharmacokinetics ofmeropenem in burn patients[J].J Antimicrob Chemother,2010,65(11):2428-2435.
  • 10Du X,Li C,Kuti JL,et al.Population pharmacokinetics andpharmacodynamics of meropenem in pediatric patients[J].J ClinPharmacol,2006,46(1):69-75.

共引文献25

同被引文献21

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部